Sonepcizumab
Sonepcizumab
Sonepcizumab (pronunciation: soh-nep-siz-uh-mab) is a monoclonal antibody designed for the treatment of various types of cancer. It works by inhibiting the growth of new blood vessels, a process known as angiogenesis, which is critical for the growth and spread of cancer cells.
Etymology
The name "Sonepcizumab" is derived from the International Nonproprietary Names (INN), where "son" refers to the target (Sphingosine-1-phosphate), "ep" indicates its use in epithelial malignancies, "ci" denotes human origin, and "mab" signifies it as a monoclonal antibody.
Mechanism of Action
Sonepcizumab binds to a protein called sphingosine-1-phosphate (S1P), which plays a key role in angiogenesis. By blocking S1P, sonepcizumab can prevent the formation of new blood vessels, thereby inhibiting the growth and spread of cancer cells.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Angiogenesis: The formation of new blood vessels.
- Sphingosine-1-phosphate (S1P): A signaling lipid involved in various cellular processes, including angiogenesis.
- Epithelial Malignancies: Cancers that begin in the cells that line the organs.
Clinical Trials
Several clinical trials have been conducted to evaluate the safety and efficacy of sonepcizumab in patients with different types of cancer. However, as of now, it is not yet approved by the Food and Drug Administration (FDA) for any specific use.
External links
- Medical encyclopedia article on Sonepcizumab
- Wikipedia's article - Sonepcizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski